Cargando…

Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study

PURPOSE: Reduced quality of life after cystectomy has made bladder preservation a popular research topic for muscle-invasive bladder cancer (MIBC). Previous research has indicated significant tumor downstaging after neoadjuvant chemotherapy (NAC). However, maximal transurethral resection of bladder...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Hongzhe, Zhang, Wen, Bi, Xingang, Wang, Dong, Xiao, Zejun, Guan, Youyan, Guan, Kaopeng, Tian, Jun, Bai, Hongsong, Hu, Linjun, Cao, Chuanzhen, Jiang, Weixing, Hu, Zhilong, Zhang, Jin, Chen, Yan, Zheng, Shan, Feng, Xiaoli, Li, Changling, Li, Yexiong, Ma, Jianhui, Liu, Yueping, Zhou, Aiping, Shou, Jianzhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524034/ https://www.ncbi.nlm.nih.gov/pubmed/33592141 http://dx.doi.org/10.4143/crt.2020.1356

Ejemplares similares

Copy number variation of urine exfoliated cells by low-coverage whole genome sequencing for diagnosis of prostate adenocarcinoma: a prospective cohort study
por: Guan, Youyan, et al.
Publicado: (2022)

Long-term survival and prognostic factors for locally advanced renal cell carcinoma with renal vein tumor thrombus
por: Cao, Chuanzhen, et al.
Publicado: (2019)

Transmembrane Transporter Sema3D Serves as a Tumor Suppressor in Localized Clear Cell Renal Cell Carcinoma
por: Xie, Ruiyang, et al.
Publicado: (2022)

Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy
por: Shang, Bingqing, et al.
Publicado: (2022)

A Muscle-Invasive Bladder Cancer Patient With High Tumor Mutational Burden and RB1 Mutation Achieved Bladder Preservation Following Chemotherapy Combined With Immunotherapy: A Case Report
por: Cao, Chuanzhen, et al.
Publicado: (2021)

Combination of Hematology Indicators and Oncological Characteristics as a New Promising Prognostic Factor in Localized Clear Cell Renal Cell Carcinoma
por: Kang, Xiangpeng, et al.
Publicado: (2020)

Novel cut‐off values of time from diagnosis to systematic therapy predict the overall survival and the efficacy of targeted therapy in renal cell carcinoma: A long‐term, follow‐up, retrospective study
por: Cao, Chuanzhen, et al.
Publicado: (2021)

Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta‐analysis of safety
por: Xie, Ruiyang, et al.
Publicado: (2022)

A novel nomogram can predict pathological T3a upstaged from clinical T1a in localized renal cell carcinoma
por: Cao, Chuanzhen, et al.
Publicado: (2022)

Prognostic value of the ratio of maximum to minimum diameter of primary tumor in metastatic clear cell renal cell carcinoma
por: Shi, Hongzhe, et al.
Publicado: (2022)

Prognostic Significance of NLR About NETosis and Lymphocytes Perturbations in Localized Renal Cell Carcinoma With Tumor Thrombus
por: Shang, Bingqing, et al.
Publicado: (2021)

Impact of Primary Tumor Size on Prognosis in Patients With Metastatic Renal Cell Carcinoma Receiving Cytoreductive Nephrectomy: A Population Study of a Chinese Center and the US SEER Database
por: Jiang, Weixing, et al.
Publicado: (2021)

Efficacy and safety of surgery in renal carcinoma patients 75 years and older: a retrospective analysis
por: Bai, Hongsong, et al.
Publicado: (2022)

Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
por: El-Taji, Omar M. S., et al.
Publicado: (2016)

Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents
por: Cao, Chuanzhen, et al.
Publicado: (2022)

CYR61 as a potential biomarker for the preoperative identification of muscle-invasive bladder cancers
por: Chen, Huang, et al.
Publicado: (2021)

Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
por: Tholomier, Côme, et al.
Publicado: (2020)

Efficacy and safety of oncolytic viruses in advanced or metastatic cancer: a network meta-analysis
por: Xie, Ruiyang, et al.
Publicado: (2021)

AB007. Bladder-sparing treatments for muscle-invasive bladder cancer
por: Li, Shengwen, et al.
Publicado: (2017)

Bladder neck sparing in radical prostatectomy
por: Smolski, Michal, et al.
Publicado: (2013)

Trimodality bladder-sparing approach without neoadjuvant chemotherapy for node-negative localized muscle-invasive urinary bladder cancer resulted in comparable cystectomy-free survival
por: Lee, Cheng-Yen, et al.
Publicado: (2014)

Comparison of Laparoscopy and Open Radical Nephrectomy of Renal Cell Cancer
por: Wang, Dong, et al.
Publicado: (2019)

Neoadjuvant Chemotherapy in Invasive Bladder Cancer
por: Oliver, R.T.D.
Publicado: (1991)

Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer
por: Witjes, J Alfred, et al.
Publicado: (2021)

Deceptive Muscle Invasive Bladder Cancer Recurrence With Benign Biopsy Foci After Bladder Sparing Treatment
por: Xu, Chuanliang, et al.
Publicado: (2015)

Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer?
por: Koga, Fumitaka
Publicado: (2020)

Association between radiotherapy and prognosis in patients with small cell carcinoma of the bladder undergoing bladder-sparing surgery
por: Liang, Fuchao, et al.
Publicado: (2023)

Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer
por: Elsayed, Dalia Hamouda, et al.
Publicado: (2023)

Bladder Sparing Therapy for BCG Failures – I – Intravesical Immunotherapy
por: Messing, Edward M.
Publicado: (2017)

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
por: Peyrottes, Arthur, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy for Different Stages of Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-analysis
por: Liu, Shuai, et al.
Publicado: (2022)

Pelvic lipomatosis: Bladder sparing extirpation of pelvic mass to relieve bladder storage dysfunction symptoms and pelvic pain
por: Ali, Ahmed, et al.
Publicado: (2014)

Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer—A Review
por: van Hattum, Jons W., et al.
Publicado: (2021)

Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives
por: Fan, Xinxiang, et al.
Publicado: (2023)

Urodynamic study of bladder function following nerve sparing radical hysterectomy
por: Maneschi, Francesco
Publicado: (2014)

Editorial: New frontiers in “bladder sparing” treatments for high risk NMIBC
por: Hurle, Rodolfo, et al.
Publicado: (2023)

Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer
por: Nassif, Elise F., et al.
Publicado: (2021)

Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer
por: Hu, Linjun, et al.
Publicado: (2020)

Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review
por: Lemiński, Artur, et al.
Publicado: (2023)

Is it oncologically and clinically safe to adopt a bladder sparing approach in complete responders following neoadjuvant chemotherapy alone without proceeding to a radical cystectomy?
por: Arianayagam, Ranjan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8dhbibplefbshcp8hiudbingms